These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2417650)

  • 41. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
    Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
    Xylinas E; Kent M; Dabi Y; Rieken M; Kluth LA; Al Hussein Al Awamlh B; Ouzaid I; Pycha A; Comploj E; Svatek RS; Lotan Y; Karakiewicz PI; Holmang S; Shariat SF
    Urol Oncol; 2018 Mar; 36(3):89.e1-89.e5. PubMed ID: 29221642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors.
    Wajsman Z; Dhafir RA; Pfeffer M; MacDonald S; Block A; Dragone N; Pontes JE
    J Urol; 1984 Jul; 132(1):30-3. PubMed ID: 6427484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases.
    Engeler DS; Wyler S; Neyer M; Hobi C; Müller J; Schmid HP
    Scand J Urol Nephrol; 2008; 42(6):522-7. PubMed ID: 18609290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.
    Feifer A; Xie X; Brophy JM; Segal R; Kassouf W
    Urology; 2010 Sep; 76(3):652-6. PubMed ID: 20394970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
    Soloway MS
    Prog Clin Biol Res; 1990; 350():71-9. PubMed ID: 2117289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
    Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
    J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group.
    Witjes JA; v d Meijden AP; Collette L; Sylvester R; Debruyne FM; van Aubel A; Witjes WP
    Urology; 1998 Sep; 52(3):403-10. PubMed ID: 9730451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer.
    Schwarzman MI; Johanson KE; Surya B; Brown J
    Urology; 1988 Oct; 32(4):335-8. PubMed ID: 3140465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
    Koontz WW; Heney NM; Soloway MS; Kluskens L; Hazra TA; Trump DL; Barton B
    Urology; 1985 Oct; 26(4 Suppl):30-1. PubMed ID: 3931326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
    Soloway MS
    J Urol; 1985 Dec; 134(6):1107-9. PubMed ID: 3932684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of mitomycin as prophylaxis following endoscopic resection of superficial bladder cancer.
    Huland H; Otto U
    Urology; 1985 Oct; 26(4 Suppl):32-5. PubMed ID: 4049627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
    Colombo R; Da Pozzo LF; Salonia A; Rigatti P; Leib Z; Baniel J; Caldarera E; Pavone-Macaluso M
    J Clin Oncol; 2003 Dec; 21(23):4270-6. PubMed ID: 14581436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term Mitomycin C is better for bladder cancer.
    Gould P
    Lancet Oncol; 2007 May; 8(5):377. PubMed ID: 17514806
    [No Abstract]   [Full Text] [Related]  

  • 59. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.
    Giannopoulos A; Constantinides C; Fokaeas E; Stravodimos C; Giannopoulou M; Kyroudi A; Gounaris A
    Clin Cancer Res; 2003 Nov; 9(15):5550-8. PubMed ID: 14654535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
    Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
    J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.